Seikagaku Keeps Momentum in International Markets

Seikagaku reported FY3Q21 orthopedic sales of ¥3,555 million ($34.1 million), +4.1% vs. FY3Q20.

The market recovery in Japan and abroad has helped the company increase sales volume. In Japan, Seikagaku is still contending with drug price reductions and the adverse side effects caused by its new JOYCLU knee osteoarthritis treatment.

The...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

ME

Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.



Contact Us

0